Date: October 24, 2025
Source: World Health Organization (WHO)
Category: Global Health & Technology
Reading time: 1 min
Building on the momentum from Seoul in 2024, the World Health Organization (WHO) and the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea co-hosted AIRIS 2025 in Incheon. The event united regulators, researchers, and industry leaders to advance the safe, ethical, and equitable use of artificial intelligence (AI) in health care.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized that as AI grows more sophisticated, global efforts must ensure its safety, effectiveness, and fairness.
Under the theme “Regulation for AI, Together for Tomorrow,” the symposium showcased leading regulatory frameworks and best practices across the medical product lifecycle—from research and clinical trials to post-market monitoring.
The AIRIS 2025 Outcome Statement called for:
- A lifecycle-based regulatory approach for AI in health products
- Risk-based frameworks tailored to each country’s health system
- Stronger global collaboration to build trust and close regulatory gaps
- Continued global dialogue through AIRIS as a recurring platform
By promoting transparency, accountability, and equitable access, AIRIS 2025 reaffirmed WHO and MFDS’s commitment to sustained collaboration for responsible AI in health — ensuring that technological innovation serves everyone safely and fairly.